Swot Analysis of "ImmuLogic Pharmaceutical Corp. (C): April 1991" written by Josh Lerner includes – strengths weakness that are internal strategic factors of the organization, and opportunities and threats that Immulogic 1991 facing as an external strategic factors. Some of the topics covered in ImmuLogic Pharmaceutical Corp. (C): April 1991 case study are - Strategic Management Strategies, Entrepreneurial management, Financial analysis, Financial management, Financial markets and Finance & Accounting.
Some of the macro environment factors that can be used to understand the ImmuLogic Pharmaceutical Corp. (C): April 1991 casestudy better are - – cloud computing is disrupting traditional business models, increasing government debt because of Covid-19 spendings, supply chains are disrupted by pandemic , increasing household debt because of falling income levels, challanges to central banks by blockchain based private currencies, there is backlash against globalization, increasing transportation and logistics costs,
banking and financial system is disrupted by Bitcoin and other crypto currencies, there is increasing trade war between United States & China, etc
Introduction to SWOT Analysis of ImmuLogic Pharmaceutical Corp. (C): April 1991
SWOT stands for an organization’s Strengths, Weaknesses, Opportunities and Threats . At Oak Spring University , we believe that protagonist in ImmuLogic Pharmaceutical Corp. (C): April 1991 case study can use SWOT analysis as a strategic management tool to assess the current internal strengths and weaknesses of the Immulogic 1991, and to figure out the opportunities and threats in the macro environment – technological, environmental, political, economic, social, demographic, etc in which Immulogic 1991 operates in.
According to Harvard Business Review, 75% of the managers use SWOT analysis for various purposes such as – evaluating current scenario, strategic planning, new venture feasibility, personal growth goals, new market entry, Go To market strategies, portfolio management and strategic trade-off assessment, organizational restructuring, etc.
SWOT Objectives / Importance of SWOT Analysis and SWOT Matrix
SWOT analysis of ImmuLogic Pharmaceutical Corp. (C): April 1991 can be done for the following purposes –
1. Strategic planning using facts provided in ImmuLogic Pharmaceutical Corp. (C): April 1991 case study
2. Improving business portfolio management of Immulogic 1991
3. Assessing feasibility of the new initiative in Finance & Accounting field.
4. Making a Finance & Accounting topic specific business decision
5. Set goals for the organization
6. Organizational restructuring of Immulogic 1991
Strengths ImmuLogic Pharmaceutical Corp. (C): April 1991 | Internal Strategic Factors
What are Strengths in SWOT Analysis / TOWS Matrix / Weighted SWOT Analysis
The strengths of Immulogic 1991 in ImmuLogic Pharmaceutical Corp. (C): April 1991 Harvard Business Review case study are -
Innovation driven organization
– Immulogic 1991 is one of the most innovative firm in sector. Manager in ImmuLogic Pharmaceutical Corp. (C): April 1991 Harvard Business Review case study can use Clayton Christensen Disruptive Innovation strategies to further increase the scale of innovtions in the organization.
Diverse revenue streams
– Immulogic 1991 is present in almost all the verticals within the industry. This has provided firm in ImmuLogic Pharmaceutical Corp. (C): April 1991 case study a diverse revenue stream that has helped it to survive disruptions such as global pandemic in Covid-19, financial disruption of 2008, and supply chain disruption of 2021.
Ability to lead change in Finance & Accounting field
– Immulogic 1991 is one of the leading players in its industry. Over the years it has not only transformed the business landscape in its segment but also across the whole industry. The ability to lead change has enabled Immulogic 1991 in – penetrating new markets, reaching out to new customers, and providing different value propositions to different customers in the international markets.
Learning organization
- Immulogic 1991 is a learning organization. It has inculcated three key characters of learning organization in its processes and operations – exploration, creativity, and expansiveness. The work place at Immulogic 1991 is open place that encourages instructiveness, ideation, open minded discussions, and creativity. Employees and leaders in ImmuLogic Pharmaceutical Corp. (C): April 1991 Harvard Business Review case study emphasize – knowledge, initiative, and innovation.
Strong track record of project management
– Immulogic 1991 is known for sticking to its project targets. This enables the firm to manage – time, project costs, and have sustainable margins on the projects.
Digital Transformation in Finance & Accounting segment
- digital transformation varies from industry to industry. For Immulogic 1991 digital transformation journey comprises differing goals based on market maturity, customer technology acceptance, and organizational culture. Immulogic 1991 has successfully integrated the four key components of digital transformation – digital integration in processes, digital integration in marketing and customer relationship management, digital integration into the value chain, and using technology to explore new products and market opportunities.
Sustainable margins compare to other players in Finance & Accounting industry
– ImmuLogic Pharmaceutical Corp. (C): April 1991 firm has clearly differentiated products in the market place. This has enabled Immulogic 1991 to fetch slight price premium compare to the competitors in the Finance & Accounting industry. The sustainable margins have also helped Immulogic 1991 to invest into research and development (R&D) and innovation.
Low bargaining power of suppliers
– Suppliers of Immulogic 1991 in the sector have low bargaining power. ImmuLogic Pharmaceutical Corp. (C): April 1991 has further diversified its suppliers portfolio by building a robust supply chain across various countries. This helps Immulogic 1991 to manage not only supply disruptions but also source products at highly competitive prices.
Superior customer experience
– The customer experience strategy of Immulogic 1991 in the segment is based on four key concepts – personalization, simplification of complex needs, prompt response, and continuous engagement.
Highly skilled collaborators
– Immulogic 1991 has highly efficient outsourcing and offshoring strategy. It has resulted in greater operational flexibility and bringing down the costs in highly price sensitive segment. Secondly the value chain collaborators of the firm in ImmuLogic Pharmaceutical Corp. (C): April 1991 HBR case study have helped the firm to develop new products and bring them quickly to the marketplace.
Effective Research and Development (R&D)
– Immulogic 1991 has innovation driven culture where significant part of the revenues are spent on the research and development activities. This has resulted in, as mentioned in case study ImmuLogic Pharmaceutical Corp. (C): April 1991 - staying ahead in the industry in terms of – new product launches, superior customer experience, highly competitive pricing strategies, and great returns to the shareholders.
High brand equity
– Immulogic 1991 has strong brand awareness and brand recognition among both - the exiting customers and potential new customers. Strong brand equity has enabled Immulogic 1991 to keep acquiring new customers and building profitable relationship with both the new and loyal customers.
Weaknesses ImmuLogic Pharmaceutical Corp. (C): April 1991 | Internal Strategic Factors
What are Weaknesses in SWOT Analysis / TOWS Matrix / Weighted SWOT Analysis
The weaknesses of ImmuLogic Pharmaceutical Corp. (C): April 1991 are -
Aligning sales with marketing
– It come across in the case study ImmuLogic Pharmaceutical Corp. (C): April 1991 that the firm needs to have more collaboration between its sales team and marketing team. Sales professionals in the industry have deep experience in developing customer relationships. Marketing department in the case ImmuLogic Pharmaceutical Corp. (C): April 1991 can leverage the sales team experience to cultivate customer relationships as Immulogic 1991 is planning to shift buying processes online.
Low market penetration in new markets
– Outside its home market of Immulogic 1991, firm in the HBR case study ImmuLogic Pharmaceutical Corp. (C): April 1991 needs to spend more promotional, marketing, and advertising efforts to penetrate international markets.
High dependence on star products
– The top 2 products and services of the firm as mentioned in the ImmuLogic Pharmaceutical Corp. (C): April 1991 HBR case study still accounts for major business revenue. This dependence on star products in has resulted into insufficient focus on developing new products, even though Immulogic 1991 has relatively successful track record of launching new products.
Slow decision making process
– As mentioned earlier in the report, Immulogic 1991 has a very deliberative decision making approach. This approach has resulted in prudent decisions, but it has also resulted in missing opportunities in the industry over the last five years. Immulogic 1991 even though has strong showing on digital transformation primary two stages, it has struggled to capitalize the power of digital transformation in marketing efforts and new venture efforts.
Ability to respond to the competition
– As the decision making is very deliberative, highlighted in the case study ImmuLogic Pharmaceutical Corp. (C): April 1991, in the dynamic environment Immulogic 1991 has struggled to respond to the nimble upstart competition. Immulogic 1991 has reasonably good record with similar level competitors but it has struggled with new entrants taking away niches of its business.
High dependence on existing supply chain
– The disruption in the global supply chains because of the Covid-19 pandemic and blockage of the Suez Canal illustrated the fragile nature of Immulogic 1991 supply chain. Even after few cautionary changes mentioned in the HBR case study - ImmuLogic Pharmaceutical Corp. (C): April 1991, it is still heavily dependent upon the existing supply chain. The existing supply chain though brings in cost efficiencies but it has left Immulogic 1991 vulnerable to further global disruptions in South East Asia.
Need for greater diversity
– Immulogic 1991 has taken concrete steps on diversity, equity, and inclusion. But the efforts so far has resulted in limited success. It needs to expand the recruitment and selection process to hire more people from the minorities and underprivileged background.
Interest costs
– Compare to the competition, Immulogic 1991 has borrowed money from the capital market at higher rates. It needs to restructure the interest payment and costs so that it can compete better and improve profitability.
Employees’ incomplete understanding of strategy
– From the instances in the HBR case study ImmuLogic Pharmaceutical Corp. (C): April 1991, it seems that the employees of Immulogic 1991 don’t have comprehensive understanding of the firm’s strategy. This is reflected in number of promotional campaigns over the last few years that had mixed messaging and competing priorities. Some of the strategic activities and services promoted in the promotional campaigns were not consistent with the organization’s strategy.
Products dominated business model
– Even though Immulogic 1991 has some of the most successful products in the industry, this business model has made each new product launch extremely critical for continuous financial growth of the organization. firm in the HBR case study - ImmuLogic Pharmaceutical Corp. (C): April 1991 should strive to include more intangible value offerings along with its core products and services.
No frontier risks strategy
– After analyzing the HBR case study ImmuLogic Pharmaceutical Corp. (C): April 1991, it seems that company is thinking about the frontier risks that can impact Finance & Accounting strategy. But it has very little resources allocation to manage the risks emerging from events such as natural disasters, climate change, melting of permafrost, tacking the rise of artificial intelligence, opportunities and threats emerging from commercialization of space etc.
Opportunities ImmuLogic Pharmaceutical Corp. (C): April 1991 | External Strategic Factors
What are Opportunities in the SWOT Analysis / TOWS Matrix / Weighted SWOT Analysis
The opportunities highlighted in the Harvard Business Review case study ImmuLogic Pharmaceutical Corp. (C): April 1991 are -
Lowering marketing communication costs
– 5G expansion will open new opportunities for Immulogic 1991 in the field of marketing communication. It will bring down the cost of doing business, provide technology platform to build new products in the Finance & Accounting segment, and it will provide faster access to the consumers.
Harnessing reconfiguration of the global supply chains
– As the trade war between US and China heats up in the coming years, Immulogic 1991 can build a diversified supply chain model across various countries in - South East Asia, India, and other parts of the world. This reconfiguration of global supply chain can help, as suggested in case study, ImmuLogic Pharmaceutical Corp. (C): April 1991, to buy more products closer to the markets, and it can leverage its size and influence to get better deal from the local markets.
Manufacturing automation
– Immulogic 1991 can use the latest technology developments to improve its manufacturing and designing process in Finance & Accounting segment. It can use CAD and 3D printing to build a quick prototype and pilot testing products. It can leverage automation using machine learning and artificial intelligence to do faster production at lowers costs, and it can leverage the growth in satellite and tracking technologies to improve inventory management, transportation, and shipping.
Learning at scale
– Online learning technologies has now opened space for Immulogic 1991 to conduct training and development for its employees across the world. This will result in not only reducing the cost of training but also help employees in different part of the world to integrate with the headquarter work culture, ethos, and standards.
Developing new processes and practices
– Immulogic 1991 can develop new processes and procedures in Finance & Accounting industry using technology such as automation using artificial intelligence, real time transportation and products tracking, 3D modeling for concept development and new products pilot testing etc.
Use of Bitcoin and other crypto currencies for transactions
– The popularity of Bitcoin and other crypto currencies as asset class and medium of transaction has opened new opportunities for Immulogic 1991 in the consumer business. Now Immulogic 1991 can target international markets with far fewer capital restrictions requirements than the existing system.
Building a culture of innovation
– managers at Immulogic 1991 can make experimentation a productive activity and build a culture of innovation using approaches such as – mining transaction data, A/B testing of websites and selling platforms, engaging potential customers over various needs, and building on small ideas in the Finance & Accounting segment.
Creating value in data economy
– The success of analytics program of Immulogic 1991 has opened avenues for new revenue streams for the organization in the industry. This can help Immulogic 1991 to build a more holistic ecosystem as suggested in the ImmuLogic Pharmaceutical Corp. (C): April 1991 case study. Immulogic 1991 can build new products and services such as - data insight services, data privacy related products, data based consulting services, etc.
Identify volunteer opportunities
– Covid-19 has impacted working population in two ways – it has led to people soul searching about their professional choices, resulting in mass resignation. Secondly it has encouraged people to do things that they are passionate about. This has opened opportunities for businesses to build volunteer oriented socially driven projects. Immulogic 1991 can explore opportunities that can attract volunteers and are consistent with its mission and vision.
Remote work and new talent hiring opportunities
– The widespread usage of remote working technologies during Covid-19 has opened opportunities for Immulogic 1991 to expand its talent hiring zone. According to McKinsey Global Institute, 20% of the high end workforce in fields such as finance, information technology, can continously work from remote local post Covid-19. This presents a really great opportunity for Immulogic 1991 to hire the very best people irrespective of their geographical location.
Increase in government spending
– As the United States and other governments are increasing social spending and infrastructure spending to build economies post Covid-19, Immulogic 1991 can use these opportunities to build new business models that can help the communities that Immulogic 1991 operates in. Secondly it can use opportunities from government spending in Finance & Accounting sector.
Redefining models of collaboration and team work
– As explained in the weaknesses section, Immulogic 1991 is facing challenges because of the dominance of functional experts in the organization. ImmuLogic Pharmaceutical Corp. (C): April 1991 case study suggests that firm can utilize new technology to build more coordinated teams and streamline operations and communications using tools such as CAD, Zoom, etc.
Better consumer reach
– The expansion of the 5G network will help Immulogic 1991 to increase its market reach. Immulogic 1991 will be able to reach out to new customers. Secondly 5G will also provide technology framework to build new tools and products that can help more immersive consumer experience and faster consumer journey.
Threats ImmuLogic Pharmaceutical Corp. (C): April 1991 External Strategic Factors
What are Threats in the SWOT Analysis / TOWS Matrix / Weighted SWOT Analysis
The threats mentioned in the HBR case study ImmuLogic Pharmaceutical Corp. (C): April 1991 are -
High dependence on third party suppliers
– Immulogic 1991 high dependence on third party suppliers can disrupt its processes and delivery mechanism. For example -the current troubles of car makers because of chip shortage is because the chip companies started producing chips for electronic companies rather than car manufacturers.
Technology disruption because of hacks, piracy etc
– The colonial pipeline illustrated, how vulnerable modern organization are to international hackers, miscreants, and disruptors. The cyber security interruption, data leaks, etc can seriously jeopardize the future growth of the organization.
Capital market disruption
– During the Covid-19, Dow Jones has touched record high. The valuations of a number of companies are way beyond their existing business model potential. This can lead to capital market correction which can put a number of suppliers, collaborators, value chain partners in great financial difficulty. It will directly impact the business of Immulogic 1991.
Backlash against dominant players
– US Congress and other legislative arms of the government are getting tough on big business especially technology companies. The digital arm of Immulogic 1991 business can come under increasing regulations regarding data privacy, data security, etc.
Aging population
– As the populations of most advanced economies are aging, it will lead to high social security costs, higher savings among population, and lower demand for goods and services in the economy. The household savings in US, France, UK, Germany, and Japan are growing faster than predicted because of uncertainty caused by pandemic.
Trade war between China and United States
– The trade war between two of the biggest economies can hugely impact the opportunities for Immulogic 1991 in the Finance & Accounting industry. The Finance & Accounting industry is already at various protected from local competition in China, with the rise of trade war the protection levels may go up. This presents a clear threat of current business model in Chinese market.
Learning curve for new practices
– As the technology based on artificial intelligence and machine learning platform is getting complex, as highlighted in case study ImmuLogic Pharmaceutical Corp. (C): April 1991, Immulogic 1991 may face longer learning curve for training and development of existing employees. This can open space for more nimble competitors in the field of Finance & Accounting .
Increasing wage structure of Immulogic 1991
– Post Covid-19 there is a sharp increase in the wages especially in the jobs that require interaction with people. The increasing wages can put downward pressure on the margins of Immulogic 1991.
Stagnating economy with rate increase
– Immulogic 1991 can face lack of demand in the market place because of Fed actions to reduce inflation. This can lead to sluggish growth in the economy, lower demands, lower investments, higher borrowing costs, and consolidation in the field.
Environmental challenges
– Immulogic 1991 needs to have a robust strategy against the disruptions arising from climate change and energy requirements. EU has identified it as key priority area and spending 30% of its 880 billion Euros European post Covid-19 recovery funds on green technology. Immulogic 1991 can take advantage of this fund but it will also bring new competitors in the Finance & Accounting industry.
Technology acceleration in Forth Industrial Revolution
– Immulogic 1991 has witnessed rapid integration of technology during Covid-19 in the Finance & Accounting industry. As one of the leading players in the industry, Immulogic 1991 needs to keep up with the evolution of technology in the Finance & Accounting sector. According to Mckinsey study top managers believe that the adoption of technology in operations, communications is 20-25 times faster than what they planned in the beginning of 2019.
Consumer confidence and its impact on Immulogic 1991 demand
– There is a high probability of declining consumer confidence, given – high inflammation rate, rise of gig economy, lower job stability, increasing cost of living, higher interest rates, and aging demography. All the factors contribute to people saving higher rate of their income, resulting in lower consumer demand in the industry and other sectors.
Shortening product life cycle
– it is one of the major threat that Immulogic 1991 is facing in Finance & Accounting sector. It can lead to higher research and development costs, higher marketing expenses, lower customer loyalty, etc.
Weighted SWOT Analysis of ImmuLogic Pharmaceutical Corp. (C): April 1991 Template, Example
Not all factors mentioned under the Strengths, Weakness, Opportunities, and Threats quadrants in the SWOT Analysis are equal. Managers in the HBR case study ImmuLogic Pharmaceutical Corp. (C): April 1991 needs to zero down on the relative importance of each factor mentioned in the Strengths, Weakness, Opportunities, and Threats quadrants.
We can provide the relative importance to each factor by assigning relative weights. Weighted SWOT analysis process is a three stage process –
First stage for doing weighted SWOT analysis of the case study ImmuLogic Pharmaceutical Corp. (C): April 1991 is to rank the strengths and weaknesses of the organization. This will help you to assess the most important strengths and weaknesses of the firm and which one of the strengths and weaknesses mentioned in the initial lists are marginal and can be left out.
Second stage for conducting weighted SWOT analysis of the Harvard case study ImmuLogic Pharmaceutical Corp. (C): April 1991 is to give probabilities to the external strategic factors thus better understanding the opportunities and threats arising out of macro environment changes and developments.
Third stage of constructing weighted SWOT analysis of ImmuLogic Pharmaceutical Corp. (C): April 1991 is to provide strategic recommendations includes – joining likelihood of external strategic factors such as opportunities and threats to the internal strategic factors – strengths and weaknesses. You should start with external factors as they will provide the direction of the overall industry. Secondly by joining probabilities with internal strategic factors can help the company not only strategic fit but also the most probably strategic trade-off that Immulogic 1991 needs to make to build a sustainable competitive advantage.